Each day in the United States, between 1,000 and 2,000 healthcare workers sustain a needlestick injury, not as a consequence of negligence or insufficient training, but because the tools available to clinicians have never fully addressed the moments of highest risk. When all healthcare settings are included, ranging from hospitals to clinics, dental offices, long-term care, and home health, studies estimate between 600,000 and 800,000 needlestick injuries occur annually in the US alone, and more than 2 million globally (1). Yet needlestick injuries (NSIs) remain among the most persistently normalized occupational hazards in medicine, accepted as an occupational inevitability rather than recognized as the preventable clinical crisis the data clearly describes.

The evidence demands a more rigorous response.

Two Million Injuries a Year. And We've Normalized It.

A 2020 meta-analysis published in the Annals of Global Health found that the pooled lifetime prevalence of NSIs among healthcare workers worldwide is approximately 44.5%, affecting nearly half of all clinicians over the course of their careers (3). Regional data reflects an even more serious burden: prevalence reaches 51% across Africa and approaches 50% among nurses in Southeast Asia (3).

These figures do not represent isolated incidents. They reflect a systemic pattern of occupational exposure that has been inadequately addressed across healthcare systems globally.

The burden is not evenly distributed. Surgical teams, emergency clinicians, nurses, and phlebotomists face disproportionate risk, particularly during phases of needle handling that have historically received insufficient attention: uncapping, recapping, and temporary needle placement during active procedures. Studies indicate that approximately 70% of needlestick injuries occur during these intra-procedural handling stages, not during the injection itself (2).

This is not primarily a training failure. It is a gap in available engineering controls.

This Is Not a Minor Injury. It Can End a Career.

Needlestick injuries expose clinicians to more than 20 bloodborne pathogens, most critically hepatitis B (HBV), hepatitis C (HCV), and HIV (4). Transmission risks are clinically significant: up to 30% for unvaccinated workers exposed to HBV, approximately 1.8% for HCV, and approximately 0.3% for HIV per percutaneous exposure (4).

Considered in isolation, these percentages may appear modest. Applied across hundreds of thousands of annual injuries, and accounting for the substantial proportion that go unreported, the cumulative clinical burden is considerable.

The consequences extend well beyond biological risk. Research documents significant psychological sequelae following NSIs, including acute anxiety during the post-exposure testing period, insomnia, guilt, fear of transmission to family members, and in some cases, post-traumatic stress symptoms that persist beyond physical recovery (5). NSIs are also a recognized contributor to clinician burnout, absenteeism, and career attrition in a healthcare workforce already operating under considerable strain.

The financial costs compound the clinical burden. Direct costs per NSI are estimated at approximately $747 globally, a figure that excludes long-term treatment, litigation, and productivity loss. In the US, the total economic burden may exceed $3 billion annually when indirect costs are incorporated (6).

The Real Numbers Are Worse Than What Gets Reported

The true scope of the NSI crisis remains difficult to quantify because a substantial proportion of injuries are never formally documented. Studies consistently estimate that 30 to 50% of needlestick injuries go unreported (5). Contributing factors include administrative burden, concern about professional consequences, and a prevailing culture in which minor sharps exposures are treated as unremarkable occupational occurrences rather than reportable safety events.

This normalization carries serious systemic consequences. Underreporting obscures the actual injury burden, delays access to post-exposure prophylaxis, and prevents institutions from identifying patterns that could inform targeted prevention strategies. Critically, it also perpetuates the cultural conditions that allow the problem to persist across successive generations of clinicians.

Accurate surveillance is not a bureaucratic exercise. It is a prerequisite for meaningful prevention.

Every Safety Device on the Market Misses the Most Dangerous Moment

Research indicates that up to 80% of sharps injuries are preventable with consistent application of safety engineering controls and evidence-based protocols (7). Despite this, injury rates remain unacceptably high across healthcare settings worldwide.

The central problem is one of scope. The safety devices most widely deployed, including retractable needles, shielded needles, and needleless IV systems, were engineered to address the post-injection phase of needle use. None of these devices provide protection during uncapping. None address the recapping phase. None stabilize the needle during intra-procedural placement.

This means the period of greatest risk, accounting for approximately 70% of all hypodermic needlestick injuries, has remained entirely unaddressed by every device category currently available (2).

OSHA's Bloodborne Pathogens Standard requires healthcare employers to evaluate and implement safer sharps devices. Until recently, however, no compliant engineering solution existed specifically for the intra-procedural handling phase that clinical data consistently identifies as the highest-risk window.

The Only Device Built for the Moment That Matters

HypoHolder, developed by KODA Ideaworks, is the first and only purpose-built device designed to address intra-procedural hypodermic needle handling. It enables one-handed uncapping, recapping, and temporary stabilization of hypodermic needles during active procedures, eliminating the two-handed techniques that represent the primary mechanism of injury during this phase.

No other device currently on the market addresses this specific clinical gap.

HypoHolder was developed by Karen Orr, a surgical PA with 25 years of operating room experience, whose direct clinical observation confirmed that the most injury-prone moments in needle handling had no engineered solution. The device is FDA-registered as a Class I exempt medical device, holds a core utility patent with a provisional filed for the disposable configuration, and is commercially available today. It supports institutional compliance with OSHA, AORN's 2025 Sharps Safety Guidelines, the Joint Commission, and Department of Defense standards.

HypoHolder is designed for integration into existing sterile and clinical workflows without retraining requirements. It does not replace existing safety devices. It addresses the phase of needle use that every other device category leaves unprotected.

The comparative picture is straightforward. Retractable needles provide no protection during uncapping or recapping. Shielded needles provide no protection during uncapping or recapping. Needleless IV systems have no application to hypodermic needle handling. HypoHolder provides engineered protection during uncapping, recapping, and intra-procedural field stabilization, requiring only one hand throughout.

Four Things Every Hospital Should Do This Year

The clinical evidence is established. The regulatory framework is in place. The engineering solution now exists. What remains is the institutional commitment to act on that evidence.

Audit NSI data with attention to underreporting. Most facilities are operating with incomplete injury records. Establishing accurate baseline data is the foundational step in any credible prevention strategy.

Prioritize engineering controls over behavioral interventions. Training and protocol adherence are necessary but insufficient on their own. Every sharp device in clinical use should be evaluated against a direct question: does this device reduce risk at the actual point of use, including during the procedure itself?

Include frontline clinicians in procurement and device selection decisions. Those with direct sharps exposure have the most accurate understanding of what functions within real clinical workflows. Procurement processes that exclude bedside input frequently result in the adoption of devices that perform poorly under operational conditions.

Treat NSI prevention as a workforce sustainability priority. The downstream effects of unaddressed sharps risk include clinician burnout, attrition, and staffing instability. Protecting clinical staff is both an ethical obligation and an operational imperative for any healthcare system managing workforce capacity and patient care continuity.

The Gap Is Closed. The Question Now Is Whether You Act.

Healthcare workers dedicate their careers to protecting patients from harm. Healthcare systems carry a reciprocal obligation to provide them with the tools and protections that make safe clinical practice possible.

Needlestick injuries are not an inevitable feature of clinical work. The majority are preventable. The most dangerous phase of hypodermic needle use, long without an engineered solution, now has one.

HypoHolder is the only device on the market that provides one-handed engineered protection during uncapping, recapping, and intra-procedural needle handling. Facilities that have not yet evaluated it are carrying a preventable and quantifiable risk.